Literature DB >> 19124114

Irritable bowel syndrome: more than abdominal pain and bowel habit abnormalities.

Brian Bond1, Judith Quinlan, George E Dukes, Fermin Mearin, Ray E Clouse, David H Alpers.   

Abstract

BACKGROUND & AIMS: Although irritable bowel syndrome (IBS) can be defined using few symptoms, principal symptoms alone may be inadequate in monitoring disorder severity. Secondary analysis of a published data set was performed to determine if more inclusive symptom measures would better reflect the burden of this disorder.
METHODS: From a prospective naturalistic study of 213 patients meeting Rome II criteria, all the data were used from daily questionnaires recorded for 4 weeks, and repeated again after an interval of 4 weeks. The total number of 11 symptoms and intensity grading score of each symptom were analyzed alongside individual symptom intensities by principal component analysis.
RESULTS: The trend accounting for the most variance was explained by the intensity of all symptoms together. The second largest trend was explained by differences between IBS bowel habits (constipation and diarrhea). The 2 constipation and 4 diarrhea symptoms closely correlated within each group, but the category of other symptoms were not correlated directly with either, and represent a separate dimension. Other symptoms (pain/discomfort, abdominal uneasiness, flatulence/distension, incomplete evacuation, pain or burning in the stomach) correlated more highly with disease intensity than either constipation or diarrhea symptoms. The sum of all symptoms and their intensity was consistent over each week, although the relative intensity of individual symptoms was more variable. Investigator measures of disease intensity underestimated that reported by patients.
CONCLUSIONS: Non-bowel habit symptoms include more than abdominal pain and discomfort, and contribute to the largest component of the total symptom burden. Thus, more than bowel habits and abdominal pain drive IBS symptom severity.

Entities:  

Mesh:

Year:  2008        PMID: 19124114      PMCID: PMC3690086          DOI: 10.1016/j.cgh.2008.08.011

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  20 in total

1.  Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.

Authors:  S A Müller-Lissner; I Fumagalli; K D Bardhan; F Pace; E Pecher; B Nault; P Rüegg
Journal:  Aliment Pharmacol Ther       Date:  2001-10       Impact factor: 8.171

2.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Authors:  M Camilleri; A R Northcutt; S Kong; G E Dukes; D McSorley; A W Mangel
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

Review 3.  Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?

Authors:  William E Whitehead; Olafur Palsson; Kenneth R Jones
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

4.  How many functional somatic syndromes?

Authors:  C Nimnuan; S Rabe-Hesketh; S Wessely; M Hotopf
Journal:  J Psychosom Res       Date:  2001-10       Impact factor: 3.006

5.  Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability.

Authors:  Fermin Mearin; Eva Baró; Montse Roset; Xavier Badía; Natalia Zárate; Isabel Pérez
Journal:  Am J Gastroenterol       Date:  2004-01       Impact factor: 10.864

6.  Chronic abdominal wall pain: clinical features, health care costs, and long-term outcome.

Authors:  Christopher D Costanza; George F Longstreth; Amy L Liu
Journal:  Clin Gastroenterol Hepatol       Date:  2004-05       Impact factor: 11.382

7.  The presentation of irritable bowel syndrome in the context of somatization disorder.

Authors:  Carol S North; Dana Downs; Ray E Clouse; Aydamir Alrakawi; Mehmet E Dokucu; Jann Cox; Edward L Spitznagel; David H Alpers
Journal:  Clin Gastroenterol Hepatol       Date:  2004-09       Impact factor: 11.382

8.  Towards positive diagnosis of the irritable bowel.

Authors:  A P Manning; W G Thompson; K W Heaton; A F Morris
Journal:  Br Med J       Date:  1978-09-02

9.  Clinical determinants of health-related quality of life in patients with irritable bowel syndrome.

Authors:  Brennan M R Spiegel; Ian M Gralnek; Roger Bolus; Lin Chang; Gareth S Dulai; Emeran A Mayer; Bruce Naliboff
Journal:  Arch Intern Med       Date:  2004-09-13

Review 10.  Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints.

Authors:  Michael Camilleri; Allen W Mangel; Sheri E Fehnel; Douglas A Drossman; Emeran A Mayer; Nicholas J Talley
Journal:  Clin Gastroenterol Hepatol       Date:  2007-04-11       Impact factor: 11.382

View more
  4 in total

1.  Subtypes of irritable bowel syndrome based on abdominal pain/discomfort severity and bowel pattern.

Authors:  Margaret Heitkemper; Kevin C Cain; Robert Shulman; Robert Burr; Anne Poppe; Monica Jarrett
Journal:  Dig Dis Sci       Date:  2011-02-03       Impact factor: 3.199

2.  Conditioned pain modulation in women with irritable bowel syndrome.

Authors:  Monica E Jarrett; Robert J Shulman; Kevin C Cain; Wimon Deechakawan; Lynne T Smith; Philippe Richebé; Margaret Eugenio; Margaret M Heitkemper
Journal:  Biol Res Nurs       Date:  2014-01-24       Impact factor: 2.522

3.  Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale.

Authors:  B Spiegel; R Bolus; L A Harris; S Lucak; B Naliboff; E Esrailian; W D Chey; A Lembo; H Karsan; K Tillisch; J Talley; E Mayer; L Chang
Journal:  Aliment Pharmacol Ther       Date:  2009-09-12       Impact factor: 8.171

4.  The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome.

Authors:  Shahin Merat; Shadi Khalili; Pardise Mostajabi; Anahita Ghorbani; Reza Ansari; Reza Malekzadeh
Journal:  Dig Dis Sci       Date:  2009-06-09       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.